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Peripheral blood mononuclear cells of breast
cancer patients can be reprogrammed to
enhance anti-HER-2/neu reactivity and overcome
myeloid-derived suppressor cells
Kyle K Payne1*, Christine K Zoon1, Wen Wan1, Khin Marlar2, Rebecca C Keim1, Mehrab Nasiri Kenari2,
Latif Kazim2, Harry D Bear1, Masoud H Manjili1
From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013

Barriers limiting the efficacy of adoptive cellular therapy
(ACT) for breast cancer patients include immune suppression mediated by myeloid-derived suppressor cells
(MDSC) and a low frequency of tumor-reactive memory
T cells (Tm). Recently, we developed an ex vivo protocol
to reprogram tumor-reactive murine splenocytes; these
cells were found to be resistant to MDSC suppression
and protected FVBN202 mice from tumor challenge.
Here, we evaluated the clinical applicability of reprogramming tumor-sensitized PBMCs isolated from
patients with early stage breast cancer by treatment with
bryostatin 1 and ionomycin (B/I) combined with IL-2,
IL-7 and IL-15. Our data demonstrate that reprogrammed
cells are enriched with Tm cells (n=5; p=0.006), as well as
activated CD56+(n=6; p=0.003) and CD161+ (n=4; p=0.02)
NKT cells, and demonstrate expansion in total cell
numbers (n=16; p=0.003) compared to baseline cells.
Reprogrammed PBMCs displayed enhanced HER-2/
neu-specific IFN-g producing immune responses (n=6;
p=0.04); non-reprogrammed control PBMC IFN-g production was not significant (n=6; p=0.4). Furthermore,
high-throughput sequencing analysis of the T cell
receptor (TcR) Vb in one patient demonstrated clonal
expansion of specific TcR VJ recombination events
resulting from cellular reprogramming, suggestive of an

enriched frequency of specific tumor antigen-primed
T cell clones. Interestingly, reprogrammed T cells were
resistant to autologous CD33 + CD11b + HLA-DR lo/MDSCs, as determined by further enhanced HER-2/
neu-specific IFN-g secretion in the presence of MDSCs
(n=6; p=0.03). Activated CD161+ NKT cells comprising
3% or greater of total reprogrammed cells rendered T cells
resistant to MDSCs (n=3; p=0.02). Upregulation of
NKG2D expression on CD161 + (n=5; p=0.0006) and
CD56+ (n=5; p=0.04) NKT cells resulted from cellular
reprogramming. Therefore, NKG2D signaling was blocked
using anti-NKG2D blocking antibody in our co-culture
system, resulting in the abrogation of resistance to MDSCs
as determined by blunted IFN-g secretion (n=3; p=0.04).
Finally, the phenotype of MDSCs after co-culture with
reprogrammed PBMC was examined; we observed downregulation of CD11b expression (n=3; p=0.02) concomitant with HLA-DR upregulation on MDSCs (n=3;
p=0.001); suggestive of induced maturation of MDSCs
into Dendritic Cells (DC). The results of our study offer
the following strategies to improve ACT of breast cancer:
i) inclusion of activated NKT cells in ACT to overcome
MDSC suppression by inducing MDSC maturation
into DCs, and ii) PBMC reprogramming to enrich the
frequency of tumor-reactive Tm cells.
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